Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Hum Nutr Diet ; 33(6): 862-868, 2020 12.
Article in English | MEDLINE | ID: mdl-32378264

ABSTRACT

BACKGROUND: Different nutritional screening instruments can be used to identify the risk of malnutrition in advanced chronic liver disease patients. The present study aimed to evaluate and compare two nutrition screening tools with the Global Leadership Initiative on Malnutrition (GLIM) diagnostic criteria for malnutrition in patients with advanced chronic liver disease. METHODS: Two nutritional screening tools, Nutritional Risk Screening 2002 (NRS-2002) and Royal Free Hospital Nutritional Prioritizing Tool (RFH-NPT), were assessed for 166 patients with liver cirrhosis. We compared medium/high nutritional risk screening with the diagnosis of malnutrition, using the GLIM criteria as the reference standard. RESULTS: According to the GLIM criteria, 57.3% of the patients were malnourished. NRS and RFH-NPT identified, respectively, 36.1% and 52.4% of patients with nutritional risk. RFH-NPT presented better agreement with the diagnosis according to GLIM criteria (k = 0.64; 95% confidence interval = 0.52-0.75), higher sensitivity (80%), higher negative predictive value (79%) and larger area under the curve (82.3%) compared to the NRS. CONCLUSIONS: RFH-NPT, when compared with the GLIM method, has substantial agreement in identifying nutritional risk, good sensitivity and good value for diagnosing malnutrition in patients with advanced chronic liver disease.


Subject(s)
End Stage Liver Disease/classification , Malnutrition/diagnosis , Mass Screening/methods , Nutrition Assessment , Risk Assessment/methods , Aged , Cross-Sectional Studies , End Stage Liver Disease/complications , End Stage Liver Disease/physiopathology , Female , Humans , Male , Malnutrition/etiology , Middle Aged , Nutritional Status , Severity of Illness Index
2.
J Hum Nutr Diet ; 29(3): 345-53, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26216648

ABSTRACT

BACKGROUND: Insulin resistance promotes liver disease progression and may be associated with a lower response rate in treated hepatitis C virus (HCV) infected patients. n-3 polyunsaturated fatty acid (PUFA) supplementation may reduce insulin resistance. The present study aimed to evaluate the effect of n-3 PUFA supplementation on insulin resistance in these patients. METHODS: In a randomised, double-blind clinical trial, 154 patients were screened. After applying inclusion criteria, 52 patients [homeostasis model assessment index of insulin resistance (HOMA-IR ≥2.5)] were randomly divided into two groups: n-3 PUFA (n = 25/6000 mg day(-1) of fish oil) or control (n = 27/6000 mg day(-1) of soybean oil). Both groups were supplemented for 12 weeks and underwent monthly nutritional consultation. Biochemical tests were performed at baseline and after intervention. Statistical analysis was performed using the Wilcoxon Mann-Whitney test for comparisons and the Wilcoxon test for paired data. Statistical package r, version 3.02 (The R Project for Statistical Computing) was used and P < 0.05 (two-tailed) was considered statistically significant. RESULTS: Comparisons between groups showed that n-3 PUFA supplementation was more effective than the control for reducing HOMA-IR (P = 0.015) and serum insulin (P = 0.016). The n-3 PUFA group not only showed a significant reduction in HOMA-IR 3.8 (3.2-5.0) versus 2.4 (1.8-3.3) (P = 0.002); serum insulin 17.1 (13.8-20.6) µIU mL(-1) versus 10.9 (8.6-14.6) µIU mL(-1) (P = 0.001); and glycated haemoglobin 5.4% (5.0-5.7%) versus 5.1% (4.8-5.6%) (P = 0.011), but also presented an increase in interleukin-1 97.5 (0.0-199.8) pg mL(-1) versus 192.4 (102.2-266.8) pg mL(-1) (P = 0.003) and tumour necrosis factor 121.2 (0.0-171.3) pg mL(-1) versus 185.7 (98.0-246.9) pg mL(-1) (P = 0.003). CONCLUSIONS: n-3 PUFA supplementation reduces insulin resistance in genotype 1 HCV infected patients.


Subject(s)
Fatty Acids, Omega-3/administration & dosage , Hepatitis C, Chronic/drug therapy , Insulin Resistance , Adolescent , Adult , Aged , Body Mass Index , Dietary Supplements , Fatty Liver/complications , Female , Fish Oils/administration & dosage , Genotype , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/complications , Humans , Insulin/blood , Male , Middle Aged
3.
J Hum Nutr Diet ; 26 Suppl 1: 7-15, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23656463

ABSTRACT

BACKGROUND: The present study aimed to evaluate the impact of animal and vegetable protein supplementation on health-related quality of life (HRQL) in patients with hepatitis C virus (HCV) and to investigate clinical and nutritional variables related to quality of life in these patients. METHODS: One hundred and forty patients infected with HCV were randomly assigned to one of two groups: the Soy Group (SG; n = 72), where patients received a soy supplement diet and the Casein Group (CG; n = 68), where patients received casein as a supplement. Anthropometric, biochemical and clinical assessments were performed in all patients, and the Short-Form Health Survey was applied at baseline and 12 weeks after study initiation. RESULTS: Before supplementation, poor HRQL scores were associated with female sex (P = 0.004) and advanced fibrosis (F3/F4; P = 0.04). Reduced HRQL scores were correlated with age (r = -0.263; P = 0.002), serum albumin levels (r = 0.245; P = 0.004), lean mass (r = 0.301; P < 0.0001) and body fat percentage (r = -0.262; P = 0.002). After 12 weeks of intervention, patients in both supplementation groups showed significantly increased HRQL scores, with no difference being observed between the SG and the CG. CONCLUSIONS: Nutritional therapy with either soybean or casein supplementation improved quality of life in patients infected with HCV. Quality of life was influenced by anthropometric, biochemical, clinical and sociodemographic factors in patients with HCV before nutritional supplementation.


Subject(s)
Caseins/therapeutic use , Dietary Proteins/therapeutic use , Dietary Supplements , Hepacivirus , Hepatitis C, Chronic/drug therapy , Quality of Life , Soybean Proteins/therapeutic use , Adipose Tissue/metabolism , Adult , Age Factors , Body Composition , Body Fluid Compartments/metabolism , Caseins/pharmacology , Dietary Proteins/pharmacology , Fibrosis , Hepatitis C, Chronic/metabolism , Hepatitis C, Chronic/pathology , Hepatitis C, Chronic/virology , Humans , Middle Aged , Serum Albumin/metabolism , Sex Factors , Soybean Proteins/pharmacology
4.
Nutr Hosp ; 27(4): 991-8, 2012.
Article in English | MEDLINE | ID: mdl-23165534

ABSTRACT

The aim of this review is to describe the molecular mechanisms of nonalcoholic fatty liver disease (NAFLD) and to present evidence regarding the mechanisms of soy-mediated therapeutic activity in preventing and treating NAFLD. NAFLD is induced by multiple metabolic pathways, including an increase in the release of fatty acids from the adipose tissue (lipolysis), insulin resistance (IR), and an increase in "de novo" fatty acid synthesis. Furthermore, NAFLD is correlated with a decrease in liver ß-oxidation, an increase in oxygen free radical production, and an increase in pro-inflammatory cytokine production, which leads to an increase in liver fat and, subsequently, to tissue damage. The bioactive compounds in soy can prevent and treat NAFLD by modulating lipid metabolism and regulating the expression of related transcription factors. Soy intake decreases the expression of sterol regulatory-element binding protein-lc (SREBP-1) and increases the expression of SREBP-2, which are transcription factors associated with the regulation of hepatic lipogenesis and reduction of cholesterol synthesis and absorption in the liver, respectively. Besides, interactions between soy components, such as standard amino acids, polyunsaturated fat, and the isoflavonoid-enriched fraction, are believed to improve fatty acid oxidation in the liver parenchyma by increasing the expression of peroxisome proliferator-activated receptor α (PPARα)-regulated genes, thus decreasing lipid accumulation in the liver. Therefore, including soy-derived foods in the diet as a therapeutic tool for patients with NAFLD might improve their clinical evolution.


Subject(s)
Fatty Liver/prevention & control , Glycine max , Animals , Diet , Humans , Lipid Metabolism/drug effects , Lipid Metabolism/physiology , Non-alcoholic Fatty Liver Disease , PPAR alpha/metabolism , Sterol Regulatory Element Binding Protein 1/metabolism , Sterol Regulatory Element Binding Protein 2/metabolism
5.
Public Health Nutr ; 10(9): 878-82, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17381936

ABSTRACT

OBJECTIVE: To evaluate the association between overweight and wheezing in pre-school children in 14 small Brazilian communities. METHODS: Cross-sectional epidemiological study, conducted between 2001 and 2002. A sample of 3453 children under 5 years of age was taken from nine communities in the state of Bahia and five in the state of São Paulo. Data on housing, family and children were obtained by applying structured questionnaires in loco. Weight and height for each child were also measured. The association between wheezing and overweight was assessed by unconditional logistic multivariate regression models. RESULTS: Overweight children had a greater frequency of wheezing and an odds ratio of 2.57 (95% confidence interval 1.51-4.37) was estimated after controlling for several potential confounding variables. The magnitude of the risk was not affected by several different model specifications. CONCLUSION: Excess weight is associated with increased risk for wheezing in this population of children below 5 years of age.


Subject(s)
Asthma/epidemiology , Overweight , Respiratory Sounds , Brazil/epidemiology , Child, Preschool , Confidence Intervals , Cross-Sectional Studies , Female , Humans , Infant , Infant, Newborn , Logistic Models , Male , Multivariate Analysis , Odds Ratio , Prevalence , Risk Factors , Rural Population/statistics & numerical data , Sex Factors , Surveys and Questionnaires , Urban Population/statistics & numerical data
SELECTION OF CITATIONS
SEARCH DETAIL
...